Payment overview · 2025
General Payments
$2,230.40
120 reported records · 21 companies
Healthcare provider profile · identity verified
David Joel Pernikoff, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAINT LOUIS, MO · NPI 1205820594
Verified facts
What the public records show
CMS Open Payments records show David Joel Pernikoff, M.D. received $2,230.40 in general payments during 2025 across 120 reported records.
GlaxoSmithKline, LLC. accounted for 17.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Gemtesa, Jardiance, Mounjaro, Ozempic, Paxlovid, Rexulti, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Linzess by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 268 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $384.76 | 17.2% | 24 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $349.08 | 15.7% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $272.44 | 12.2% | 20 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $226.21 | 10.1% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $196.69 | 8.8% | 13 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $164.62 | 7.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $132.64 | 6.0% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $93.16 | 4.2% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $73.70 | 3.3% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $62.56 | 2.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $53.13 | 2.4% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $42.23 | 1.9% | 3 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $24.44 | 1.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $24.43 | 1.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.95 | 1.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $22.19 | 1.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.92 | 0.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.59 | 0.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.80 | 0.7% | 1 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $15.48 | 0.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.38 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,210.18 | 119 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $384.76 | 24 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $291.23 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $248.11 | 17 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $218.30 | 15 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $167.68 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $164.62 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $162.52 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $134.75 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $132.64 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $130.65 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $121.85 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $118.78 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $115.69 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $111.40 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $68.55 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $44.09 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $43.75 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $42.23 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $37.64 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $29.81 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $24.43 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $4.17 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 46 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 268 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 182 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 182 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 144 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 14 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 141 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
182 | 51 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
46 | 45 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
141 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
182 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
182 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
144 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
268 | 55 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1469 | 441 |
| Amlodipine Besylate | Amlodipine Besylate | 1002 | 296 |
| Losartan Potassium | Losartan Potassium | 556 | 169 |
| Lisinopril | Lisinopril | 531 | 166 |
| Levothyroxine Sodium | Levothyroxine Sodium | 508 | 124 |
| Metformin Hcl | Metformin Hcl | 476 | 132 |
| Potassium Chloride | Potassium Chloride | 436 | 150 |
| Furosemide | Furosemide | 379 | 120 |
| Hydrochlorothiazide | Hydrochlorothiazide | 358 | 107 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 335 | 105 |
| Omeprazole | Omeprazole | 330 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 310 | 98 |
| Tramadol Hcl | Tramadol Hcl | 307 | 99 |
| Alprazolam | Alprazolam | 306 | 66 |
| Famotidine | Famotidine | 305 | 98 |
| Metoprolol Tartrate | Metoprolol Tartrate | 295 | 85 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 292 | 64 |
| Eliquis | Apixaban | 268 | 55 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 258 | 84 |
| Carvedilol | Carvedilol | 251 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 243 | 70 |
| Gabapentin | Gabapentin | 242 | 94 |
| Fluticasone Propionate | Fluticasone Propionate | 230 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 221 | 80 |
| Meloxicam | Meloxicam | 204 | 62 |
| Allopurinol | Allopurinol | 201 | 67 |
| Ezetimibe | Ezetimibe | 185 | 60 |
| Zolpidem Tartrate | Zolpidem Tartrate | 185 | 29 |
| Jardiance | Empagliflozin | 182 | 51 |
| Mounjaro | Tirzepatide | 182 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 172 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 150 | 58 |
| Spironolactone | Spironolactone | 149 | 45 |
| Simvastatin | Simvastatin | 145 | 47 |
| Metformin Hcl Er | Metformin Hcl | 144 | 44 |
| Ozempic | Semaglutide | 144 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 143 | 51 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 141 | 33 |
| Sertraline Hcl | Sertraline Hcl | 125 | 36 |
| Montelukast Sodium | Montelukast Sodium | 116 | 33 |
| Trazodone Hcl | Trazodone Hcl | 116 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 111 | 40 |
| Chlorthalidone | Chlorthalidone | 110 | 39 |
| Prednisone | Prednisone | 107 | 56 |
| Diclofenac Sodium | Diclofenac Sodium | 102 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 102 | 37 |
| Alendronate Sodium | Alendronate Sodium | 98 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 27 |
| Meclizine Hcl | Meclizine Hcl | 95 | 34 |
| Pregabalin | Pregabalin | 94 | 30 |
| Lorazepam | Lorazepam | 93 | 21 |
| Azithromycin | Azithromycin | 90 | 68 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 31 |
| Celecoxib | Celecoxib | 85 | 28 |
| Glipizide | Glipizide | 83 | 24 |
| Amoxicillin | Amoxicillin | 82 | 61 |
| Memantine Hcl | Memantine Hcl | 80 | 25 |
| Methylprednisolone | Methylprednisolone | 80 | 69 |
| Ibuprofen | Ibuprofen | 79 | 31 |
| Buspirone Hcl | Buspirone Hcl | 77 | 24 |
| Donepezil Hcl | Donepezil Hcl | 77 | 30 |
| Finasteride | Finasteride | 77 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 17 |
| Glimepiride | Glimepiride | 69 | 20 |
| Mirtazapine | Mirtazapine | 68 | 24 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 62 | 49 |
| Cilostazol | Cilostazol | 59 | 16 |
| Entresto | Sacubitril/Valsartan | 58 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 58 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 17 |
| Trulicity | Dulaglutide | 56 | 11 |
| Valacyclovir | Valacyclovir Hcl | 55 | 27 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 54 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 51 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 16 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 50 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 11 |
| Myrbetriq | Mirabegron | 50 | suppressed |
| Linzess | Linaclotide | 49 | 13 |
| Klor-Con M20 | Potassium Chloride | 48 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 16 |
| Warfarin Sodium | Warfarin Sodium | 48 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 47 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 15 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 47 | 13 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 46 | 45 |
| Naproxen | Naproxen | 45 | 13 |
| Rexulti | Brexpiprazole | 44 | suppressed |
| Topiramate | Topiramate | 43 | 13 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 43 | 13 |
| Folic Acid | Folic Acid | 41 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 40 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 39 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 39 | 12 |
| Tradjenta | Linagliptin | 39 | suppressed |
| Nifedipine Er | Nifedipine | 38 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | suppressed |
| Bumetanide | Bumetanide | 37 | suppressed |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 37 | suppressed |
| Atenolol | Atenolol | 36 | 12 |
| Clonazepam | Clonazepam | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | 13 |
| Benzonatate | Benzonatate | 35 | 29 |
| Latanoprost | Latanoprost | 35 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 34 | 15 |
| Nystatin | Nystatin | 32 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | 13 |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Fluconazole | Fluconazole | 30 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | suppressed |
| Cephalexin | Cephalexin | 28 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | 16 |
| Clobetasol Propionate | Clobetasol Propionate | 27 | 11 |
| Diclofenac Potassium | Diclofenac Potassium | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 14 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 26 | 14 |
| Estradiol | Estradiol | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 26 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Mirabegron Er | Mirabegron | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 22 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Gemtesa | Vibegron | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Pentoxifylline | Pentoxifylline | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Klor-Con M10 | Potassium Chloride | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Zaleplon | Zaleplon | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,230.40 · 120 records | GlaxoSmithKline, LLC. | AREXVY, Auvelity, CAPLYTA, Cologuard Collection Kit, ELIQUIS, Fibroscan, GEMTESA, GVOKE HYPOPEN, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PURAPLY WOUND MATRIX, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, VYNDAQEL, Wegovy, YUPELRI, ZAVZPRET, ZEPBOUND, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error